U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...
Medscape

New First-Line Option for Advanced Bladder Cancer

The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for ...
Fierce Pharma

Star Padcev-Keytruda combo expands bladder cancer reach with FDA approval, pressuring AstraZeneca

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
FiercePharma

AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday clearing its PD-L1 inhibitor Imfinzi as part of the first immunotherapy combo ...
Morning Overview on MSN

Regulators cleared Keytruda with chemo before and after surgery for aggressive bladder cancer

Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the ...
WebMD

Inlexzo: A New Bladder Cancer Treatment That Delivers Medicine Directly in the Bladder

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...
STAT

Bladder cancer treatment landscape is advancing, at last

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...